High-LET radiotherapy for adenoid cystic carcinoma of the head and neck : 15 years' experience with raster-scanned carbon ion therapy
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved..
PURPOSE: Locoregional control (LC) in malignant salivary gland tumors is dose-dependent, initial results with particle therapy were promising. We report our experience with raster-scanned, intensity-controlled carbon ion therapy (C12) and IMRT in 309 patients with pathologically confirmed adenoid cystic carcinoma (ACC) of the head and neck.
PATIENTS AND METHODS: Treatment records of patients treated with C12 between 08/1998 and 05/2013 were evaluated regarding tumor stage, treatment, toxicity (CTCAE v3), LC, progression-free survival (PFS) and overall survival (OS). Response assessment was carried out according to RECIST1.1.
RESULTS: Tumor stages were mostly advanced (T4a/b: 60%, macroscopic disease: 71%), most common sites of origin were the paranasal sinus (37%). At a median follow-up at 33.9 months, LC, PFS, and OS at 3 and 5 year estimates are 83.7%/58.5%, 67.8%/56.1%, and 88.9%/74.6%. LC correlates with T-stage but neither nodal stage, age, relapse state, nor margin status. RECIST did not correlate with LC or survival rates.
CONCLUSION: IMRT plus C12 boost results in good control and survival rates at moderate toxicity. Margin status did not correlate with LC in T4 tumors, extensive and potentially mutilating surgical procedures may have to be re-evaluated. RECIST assessment did not correlate with either LC or survival rates; potentially more meaningful radiological parameters need to be developed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:118 |
|---|---|
| Enthalten in: |
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology - 118(2016), 2 vom: 01. Feb., Seite 272-80 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jensen, Alexandra D [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
ACC |
|---|
| Anmerkungen: |
Date Completed 13.12.2016 Date Revised 10.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.radonc.2015.05.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM250786869 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM250786869 | ||
| 003 | DE-627 | ||
| 005 | 20231224160600.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.radonc.2015.05.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0836.xml |
| 035 | |a (DE-627)NLM250786869 | ||
| 035 | |a (NLM)26164774 | ||
| 035 | |a (PII)S0167-8140(15)00245-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jensen, Alexandra D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High-LET radiotherapy for adenoid cystic carcinoma of the head and neck |b 15 years' experience with raster-scanned carbon ion therapy |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.12.2016 | ||
| 500 | |a Date Revised 10.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2015 Elsevier Ireland Ltd. All rights reserved. | ||
| 520 | |a PURPOSE: Locoregional control (LC) in malignant salivary gland tumors is dose-dependent, initial results with particle therapy were promising. We report our experience with raster-scanned, intensity-controlled carbon ion therapy (C12) and IMRT in 309 patients with pathologically confirmed adenoid cystic carcinoma (ACC) of the head and neck | ||
| 520 | |a PATIENTS AND METHODS: Treatment records of patients treated with C12 between 08/1998 and 05/2013 were evaluated regarding tumor stage, treatment, toxicity (CTCAE v3), LC, progression-free survival (PFS) and overall survival (OS). Response assessment was carried out according to RECIST1.1 | ||
| 520 | |a RESULTS: Tumor stages were mostly advanced (T4a/b: 60%, macroscopic disease: 71%), most common sites of origin were the paranasal sinus (37%). At a median follow-up at 33.9 months, LC, PFS, and OS at 3 and 5 year estimates are 83.7%/58.5%, 67.8%/56.1%, and 88.9%/74.6%. LC correlates with T-stage but neither nodal stage, age, relapse state, nor margin status. RECIST did not correlate with LC or survival rates | ||
| 520 | |a CONCLUSION: IMRT plus C12 boost results in good control and survival rates at moderate toxicity. Margin status did not correlate with LC in T4 tumors, extensive and potentially mutilating surgical procedures may have to be re-evaluated. RECIST assessment did not correlate with either LC or survival rates; potentially more meaningful radiological parameters need to be developed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a ACC | |
| 650 | 4 | |a Adenoid cystic carcinoma | |
| 650 | 4 | |a Carbon ion therapy | |
| 650 | 4 | |a Carbon ions | |
| 650 | 4 | |a IMRT | |
| 650 | 4 | |a MSGTs | |
| 650 | 4 | |a Malignant salivary gland tumors | |
| 650 | 4 | |a Raster-scanning | |
| 700 | 1 | |a Poulakis, Melanie |e verfasserin |4 aut | |
| 700 | 1 | |a Nikoghosyan, Anna V |e verfasserin |4 aut | |
| 700 | 1 | |a Welzel, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Uhl, Matthias |e verfasserin |4 aut | |
| 700 | 1 | |a Federspil, Philippe A |e verfasserin |4 aut | |
| 700 | 1 | |a Freier, Kolja |e verfasserin |4 aut | |
| 700 | 1 | |a Krauss, Jürgen |e verfasserin |4 aut | |
| 700 | 1 | |a Höss, Angelika |e verfasserin |4 aut | |
| 700 | 1 | |a Haberer, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Jäkel, Oliver |e verfasserin |4 aut | |
| 700 | 1 | |a Münter, Marc W |e verfasserin |4 aut | |
| 700 | 1 | |a Schulz-Ertner, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Huber, Peter E |e verfasserin |4 aut | |
| 700 | 1 | |a Debus, Jürgen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology |d 1993 |g 118(2016), 2 vom: 01. Feb., Seite 272-80 |w (DE-627)NLM012598305 |x 1879-0887 |7 nnns |
| 773 | 1 | 8 | |g volume:118 |g year:2016 |g number:2 |g day:01 |g month:02 |g pages:272-80 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.radonc.2015.05.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 118 |j 2016 |e 2 |b 01 |c 02 |h 272-80 | ||